Importantly, the application of this methodology to the tumor specimens obtained in the CAIRO2 study (in this study the colon cancer patients were treated with standard chemotherapy plus anti-EGFR antibodies) showed that among the KRAS-WT and BRAF-WT not all patients experienced benefits from the treatment with anti-EGFR antibodies: in fact, the benefit was limited to colon cancer patients with KRAS/BRAF WT epithelial-like tumors, but not KRAS/BRAF WT mesenchymal-like tumors [255]. This evidence concerns the gene BRAF and neoplasm.